tbuckley/cabot-search huggingface dataset:
PTU-157 Her2 Positivity in upper Gastrointestinal Tumours in a Large Multi-Centre UK Cohort Identifies Similar Positivity Rates but different Trends than Previously Reported and Suggests new Potential Avenues for her2 Therapies
Authors: M A Butt, M Gandy, R J Haidry, E S Bloom, S Mackie, M S Khan, J Louis-Auguste, D Oukrif, S-U-R Khan, R Saraswati, M R Banks, M Rodriguez-Justo, L B Lovat, M Novelli
Journal: Gut (2013)

<h3>Introduction</h3> Evaluation of HER2 status is standard practise for people with inoperable locally advanced or recurrent and/or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GOJ). HER2 positivity is defined as a histology score of 3+, or 2+ with HER2 gene amplification. This study analysed gastroesophageal HER2 testing in UCL-AD over the past 2.5 years. <h3>Methods</h3> All referrals for HER2 testing (n = 844) were reviewed. Data was captured for age (n = 367), sex (n = 320), tumour origin (n = 104), referring lab (n = 768), sample adequacy, HER2 grading (0–3+) and tumour type. Sections were immunostained with the Roche Tissue Diagnostics Pathway HER2 assay. For cases scoring 2+, F/DDISH testing was performed and the turn-around-time (TAT) from receipt to result analysed. <h3>Results</h3> Cases were received from 61 labs, mean age 63yo (26–93yo, SD = 13) and the majority were men (71.5%). Specimens originated from oesophageal (OE) (33.7%), GOJ (13.5%), stomach (48%) and UGI metastases (4.8%). The majority (98.7%, n = 833) were HER2-graded. The tumour types were intestinal (INT) (49.6%, n = 257), diffuse (D) (29%, n = 150), mixed D/INT (14.3%, n = 74), carcinoma-in-situ (HGD/IMC) (6.4%, n = 33), squamous (Sq) and adenosquamous (ASq) (0.4%, n = 2 each). HER2 scores were 0 (44%, n = 366), 1+ (14.5%, n = 121), 2+ (18.8%, n = 156) and 3+ (22.7%, n = 189).Gene amplification of 2+ cases identified 124 (79.5%) negative, 23 (14.7%) positive and 9 (1.1%) unrecordable results. HER2 positivity (3+/2+&amp;F/DDISH+) was noted in 10% (15/150) of D, 30.4% (78/257) of INT, 13.5% (10/74) of mixed D/INT, 54.5% (18/33) of HGD/IMC and in 50% (1/2) of Sq tumours. A TAT of &lt; 5days was achieved in 97% of cases not requiring in situ, and &lt; 10days in 97.5% requiring F/DDISH. <h3>Conclusion</h3> Overall HER2-positivity rate was 25.8% in a cohort twice the size of the UK cohort reported in the benchmark ToGA trial. When compared with ToGA, subgroup analysis showed comparable but higher rates in D cancers (10% vs 6.1%), lower in both INT/mixed cancers (30.4/13.5% vs 32.2/20.4%), showed opposite proportions of GOJ/stomach cancers (28.6/31.3% vs 33.1/20.9%), and grouping proximal (OE+GOJ) cancers together, a higher ratio compared to stomach cancers was seen (0.51 vs 0.33). Positivity in Sq cancer is of uncertain significance and warrants further research into new potential applications for HER2 targeting. <h3>Disclosure of Interest</h3> None Declared
National survey of physicians practice patterns: Fertility preservation and cancer patients
Authors: G. Quinn, S. T. Vadaparampil, P. Jacobsen, J. Lee, J. Lancaster, G. Bepler, D. L. Keefe, T. L. Albrecht
Journal: Journal of Clinical Oncology (2009)

CRA9508 Background: Addressing the impact of cancer treatment on fertility is a high priority in providing quality cancer care to patients of childbearing age. Evidence suggests less than 50% of patients receive adequate fertility information prior to cancer treatment. This study assessed the practice patterns of physicians and identified perceptions of barriers to communication about fertility. Methods: A 37 item survey was developed by a review of the literature and previous qualitative interviews. A random sample of physicians from the American Medical Association Masterfile was stratified by board specialty related to oncology. Three waves of surveys were distributed across the United States. The domains of the survey included demographics, knowledge, attitudes and practice behaviors related to FP with patients of childbearing age. Results: Of 1,979 physicians identified, a total of 613 physicians completed the survey, yielding a 33% response rate among oncologists. Oncologists with favorable attitudes towards FP were 4.9 times more likely to discuss the impact of cancer treatment on future fertility than those who have unfavorable attitudes. GYN or Medical/Hematological oncologists were 2.1 times more likely than other specialists to report feeling comfortable discussing FP with their patients. The majority of oncologists reported discussing FP with patients and indicated the primary barrier to discussion was a patient too ill to delay treatment. However, less than 25% of oncologists report referring patients for FP and only 38% report knowledge of the ASCO guidelines suggesting oncologists should discuss FP and refer all patients of childbearing age. Less than 25% of physicians surveyed reported distributing educational materials regarding FP. Conclusions: The majority of physicians in this survey report discussing FP; however they are not consulting specialists or providing educational materials to their patients. Future research will include the development of physician and nurse training curricula and interventions to facilitate discussion of FP between physicians and cancer patients. No significant financial relationships to disclose.
ALLEGED INFIDELITY OF PHYSICIANS.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OC-093 Reduced surgical resection rates with increasing immunosuppressant use in a population-based inflammatory bowel disease (IBD) cohort in Cardiff (1988–2003): Abstract OC-093
Authors: A V Ramadas, C Gwinnutt, G Thomas, G T Williams, A B Hawthorne
Journal: Gut (2010)

<h3>Introduction</h3> The benefits of immunosuppressant (IS) therapy in IBD have been demonstrated in many controlled trials, however it has been difficult to show that early and widespread use of these drugs have reduced surgical rates in routine practice. <h3>Methods</h3> To assess changes in surgical rates in IBD in a population-based cohort of IBD patients diagnosed in Cardiff between 1988 and 2003. Case notes of Crohn9s disease (CD), ulcerative colitis (UC) and indeterminate colitis (IC) patients from IBD incidence studies in Cardiff were reviewed retrospectively for disease characteristics and for follow-up information on the use of IS and the need for surgery for IBD. The patients were identified from the incidence studies of CD (1986–2005), UC and IC (1988–2007). We excluded UC and IC patients with isolated proctitis at diagnosis as surgery is rarely performed for isolated proctitis. The study population was divided into two groups (Group A=1988–1995 and Group B=1996–2003) based on the year of diagnosis. <h3>Results</h3> 553 IBD patients (Group A=259 and Group B=294) included in the final analysis. There were 309 CD, 214 UC and 30 IC patients. 5-year follow-up was available in 514 patients (93%). No significant difference in patient or disease characteristics in the two groups. Kaplan-Meier (KM) analysis showed a significant increase in cumulative probability of IS use in IBD over time; At 5 years this was 17% (Group A) and 45% (Group B) (p=0.0001). KM analysis also showed a significant decrease in surgical rates over time; At 5 years this was 47% in Group A and 28% in Group B (p=0.0001). Also there was a significant reduction in resection rates in CD (p=0.0001) and UC (p=0.02) over time in the two groups. Cox multivariate analysis of surgical interventions in IBD showed time of diagnosis (p=0.001), early steroid use (within 3 months of diagnosis) (p=0.0001) and thiopurine use within first year of diagnosis (p=0.002) as independent factors predicting resection (see Abstract 093). <h3>Conclusion</h3> The decrease in surgical resections in UC and CD in this population-based cohort over the past 18 years is most likely due to the increased and earlier use of IS therapy.
Medical problems of adults who were sexually abused in childhood.
Journal: BMJ (1990)

patients aged 80 or more.Although there is un- certainty about the exact criteria for thrombolytic treatment, the second international study of infarct survival (ISIS-2) showed some benefit for patients treated up to 24 hours after the onset of symptoms, and age was no contraindication to treatment.' Our results suggest that while most general practitioners are aware of the potential benefits of thrombolysis, they may be denying the treatment to considerable numbers of patients whom they do not admit to hospital.We suggest that, although domiciliary thrombolytic treatment might be appropriate in certain circumstances, it is more important that general practitioners modify their referral patterns so that thrombolysis is available to all patients within 24 hours of the onset of symptoms.
School Books on Physiology and Hygiene.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunologic effects of anti‐D (WinRho‐SD) in children with immune thrombocytopenic purpura
Authors: Sherri A. Zimmerman, Frank J. Malinoski, Russell E. Ware
Journal: American Journal of Hematology (1998)

Intravenous immunoglobulin (IVIG) is an effective treatment for immune thrombocytopenic purpura (ITP) that induces transient blockade of the reticuloendothelial system (RES) with additional effects including alteration of T lymphocyte subsets and suppression of in vitro T lymphocyte proliferation. As anti-D also is an effective treatment for ITP, we investigated its in vitro and in vivo immunologic effects. The in vitro effects of various agents used in ITP therapy were compared using T lymphocyte proliferation assays. Anti-D caused significantly less inhibition than IVIG or dexamethasone, but non-specific protein was as suppressive as IVIG. Six children with chronic ITP were studied following anti-D administration. Patients received a single dose of anti-D (WinRho-SD, 50 μg/kg IV over 5 min) and were studied on day 0, day 7, and 1 month later. Anti-D did not affect T lymphocyte subsets including the T cell receptor variable beta repertoire, in vitro T lymphocyte proliferation to mitogens, recall antigens, or interleukin-2, in vitro IgG synthesis induced by pokeweed mitogen, or T lymphocyte cytokine mRNA levels. We conclude that anti-D has no demonstrable in vitro or in vivo effects on lymphocyte enumeration or function, and therefore likely is effective in the treatment of ITP primarily through RES blockade. Am. J. Hematol. 57:131–138, 1998. © 1998 Wiley-Liss, Inc.
From &lt;emph type="ital"&gt;JAMA&lt;/emph&gt; ’s Daily News Site
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: A large case‐control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance
Journal: Hepatology (2016)

Lai, and Man-Fung Yuen, described the hepatitis B surface antigen (HBsAg) kinetics prior to HBsAg seroclearance in treatment-naive chronic hepatitis B (CHB), as well as factor predictive of HBsAg seroclearance.The authors concluded that serum HBsAg <200 IU/mL was predictive of subsequent HBsAg seroclearance.It was recently brought to the authors' attention that there was an error in the description of patient disposition under Patients and Methods.Paragraph 1 should have read "In our two previous studies, we investigated the clinical characteristics of 92 and 298 Chinese CHB patients with HBsAg seroclearance.One hundred and twelve of these treatment-naive patients with HBsAg seroclearance documented between June 2001 and December 2006. . .."We are grateful to the readers who brought the error to our attention.It remained true that all 203 CHB patients achieving HBsAg seroclearance were treatment-naive without the inclusion of any patients with prior treatment and that our findings reflect factors predictive of HBsAg seroclearance in treatment-naive CHB.
Typographical Error in: A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator
Authors: Juergen Kuschyk, Dariusch Haghi, Martin Borggrefe, Christian Wolpert, Joachim Brade, Haghi Borggrefe
Journal: JAMA (2007)

achieve speeds greater than 200 km per hour and acceleration forces of 6g. 3 In a systematic evaluation of 40 roller coaster fatalities over a 10-year period, at least 7 deaths were attributed to cardiac causes. 4Although the arrhythmias observed in our study of healthy individuals were benign, the magnitude of increase in heart rate raises the possibility of risk for individuals with underlying cardiac disease.
AIDS Clinical Trials Group Study Numbers
Authors: Margaret A. Fischl
Journal: Annals of Internal Medicine (1995)

Letters1 September 1995AIDS Clinical Trials Group Study NumbersMargaret A. Fischl, MD, Kenneth Stanley, PhD, and Ann C. Collier, MDMargaret A. Fischl, MDUniversity of Miami School of Medicine; Miami, FL 33101Harvard School of Public Health; Boston, MA 02115University of Washington; Seattle, WA 98104Search for more papers by this author, Kenneth Stanley, PhDUniversity of Miami School of Medicine; Miami, FL 33101Harvard School of Public Health; Boston, MA 02115University of Washington; Seattle, WA 98104Search for more papers by this author, and Ann C. Collier, MDUniversity of Miami School of Medicine; Miami, FL 33101Harvard School of Public Health; Boston, MA 02115University of Washington; Seattle, WA 98104Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-5-199509010-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. von Reyn proposes an interesting precedent. We had not initially included the ACTG protocol number for this study to avoid ACTG jargon or vernacular. However, Dr. von Reyn is correct in that presentations and discussions of ACTG studies frequently refer to these studies by their ACTG protocol number. Dr. von Reyn has also correctly cited our study [1] as ACTG 155.References1. Fischi MA. Stanley K, Collier AC, Ardunio JM, Stein DS, Feinberg JE, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advance HIV disease. Ann Intern Med. 1995; 122:24-32. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Miami School of Medicine; Miami, FL 33101Harvard School of Public Health; Boston, MA 02115University of Washington; Seattle, WA 98104 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1995Volume 123, Issue 5Page: 395KeywordsAIDSClinical trials Issue Published: 1 September 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
A Correction to the Research Article Titled: “Impaired Sphingolipid Synthesis in the Respiratory Tract Induces Airway Hyperreactivity” by T. S. Worgall, A. Veerappan, B. Sung, B. I. Kim, E. Weiner, R. Bholah, R. B. Silver, X.-C. Jiang, S. Worgall
Journal: Science Translational Medicine (2013)
Pneumonia Verminose: Studio Radiologic e Pathologic de Bilharziasis Chronic in Gerbos Experimental
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Methicillin-Resistant Staphylococcus Aureus in a General Intensive Care Unit
Authors: D S Thompson
Journal: Journal of the Royal Society of Medicine (2004)

Methicillin-resistant Staphylococcus aureus (MRSA) has presented special problems in intensive care units (ICUs) because of the difficulties in implementing infection control measures. The prevalence and rate of acquisition of MRSA were studied over thirty months in a nine-bed ICU. Nasal and groin swabs were taken on admission and then weekly, and other cultures as clinically indicated. Of 1361 admissions 119 were MRSA-positive on arrival. 21 cases had been identified before admission and the remainder were detected by screening; in 57 the positive result was known only after discharge. Of the 1242 admissions initially negative 68 acquired MRSA while in the ICU. The ICU had no known MRSA-positive patients on 185 (20.3%) of 914 days, the longest sequence being 17 days. Positive patients occupied 1387 (16.9%) of the 8226 available bed days. Length of stay predicted the risk of acquiring MRSA. Estimated from patients who completed each weekly screening cycle, the risk was 7.5% per week in the first week and 20.3% per week thereafter. The risk was not influenced by initial APACHE II score, the use of haemofiltration, or the number of MRSA-positive patients in the unit. The data suggest that a further 38 of those discharged between weekly screenings acquired MRSA, giving an incidence of 8.5%. MRSA was grown from blood in 17 patients, and from sputum in 53 (ICU-acquired in 18% and 47%). This study suggests that nearly 10% of admissions to a general ICU will be MRSA-positive, of whom only half will be identified before discharge. With standard prevention the risk of previously negative patients acquiring MRSA approximates to 1% per day in the first week and 3% per day thereafter, with nearly one-fifth progressing to bacteraemia; one-half will have MRSA in sputum. Patients with longer stays constitute a high-risk minority for whom additional measures such as decontamination with oropharyngeal and enteral vancomycin should be considered.
MYCOSIS FUNGOIDES
Authors: LAURENCE POTTS
Journal: British Journal of Dermatology (1901)

Journal Article MYCOSIS FUNGOIDES Get access LAURENCE POTTS, M.R.C.S. LAURENCE POTTS, M.R.C.S. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 13, Issue 8, 1 August 1901, Pages 309–310, https://doi.org/10.1111/j.1365-2133.1901.tb16400.x Published: 01 August 1901
Style Matters: Advertising in medical journals
Journal: BMJ (1993)

Cost-effectiveness analysis is a form of economic evaluation in which the costs of alternative procedures or programmes are compared with outcomes measured in natural units-for example, cost per life year saved, cost per case cured, cost per symptom free day * Effectiveness data are ideally collected from economic evaluations built in alongside clinical trials.In the absence of dedicated trials researchers need to draw on the existing published work * Sensitivity analysis should be applied when there is uncertainty about the costs and effectiveness of different procedures.This investigates the extent to which results are sensitive to alternative assumptions about key variables * There is debate among economists about whether benefit measures should be "time discounted" in the same way as costs.If they are not, whereas costs are, projects with long lasting effects will become relatively more cost effective-for example, maternity services and health promotion.But it is probably too early to recommend this as a standard practice
Impact of sex ratio on onset and management of labour
Authors: M. H Hall, R. A Carr-Hill
Journal: BMJ (1982)

In a study of 52 266 live singleton deliveries in a total population male babies were delivered at earlier gesta- tions than female.This difference was not due to induc- tion or elective caesarean section.Female babies were more likely to present and be delivered by the breech.When the presentation was cephalic, male babies were much more likely to be delivered by forceps or caesarean section and female babies to deliver spontaneously.